Key takeaways
Bimzelx (bimekizumab) and Cosentyx (secukinumab) are both medications used to treat plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa, among other conditions. And they both belong to the interleukin inhibitor medication class. However, they have some differences. Bimzelx is specifically an interleukin antagonist that blocks IL-17A and IL-17F, while Cosentyx is an IL-17 inhibitor. Bimzelx is typically injected every month or every other month, while Cosentyx is injected weekly for the first five weeks and then monthly. Both medications are available as prefilled syringes or pens, but Cosentyx can also be given as an infusion. Common side effects of Bimzelx include upper respiratory infections and oral thrush, while Cosentyx may cause common cold symptoms and diarrhea. Both medications can increase the risk of infections due to their effects on the immune system.
